Research analysts covering NuCana.
Recent press releases and 8-K filings for NCNA.
NuCana plc Presents Latest Clinical Data for NUC-7738
NCNA
New Projects/Investments
- NuCana plc presented the latest clinical data for NUC-7738 in combination with pembrolizumab in patients with PD-1 inhibitor-resistant metastatic melanoma at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025.
- The data demonstrated clinical activity and a favorable safety profile, reinforcing earlier findings.
- Clinical activity observed includes two partial responses (one confirmed) and seven cases of stable disease, with one ongoing stable disease converting to a complete metabolic response.
- No new safety signals have been observed, and several patients remain on therapy with ongoing disease control.
- The Expansion Cohort has treated nine patients, contributing to a planned total combination dataset of up to 40 patients.
Dec 10, 2025, 1:15 PM
NuCana plc Reports Q3 2025 Financial Results and Provides Business Update
NCNA
Earnings
Guidance Update
New Projects/Investments
- NuCana plc reported a net loss of £0.3 million for the third quarter ended September 30, 2025, compared to a net loss of £4.5 million for the same period in 2024, with basic and diluted loss per ordinary share at £0.00.
- The company's cash and cash equivalents stood at £25.2 million as of September 30, 2025, and it anticipates this will provide a cash runway into 2029. This position was strengthened by £19.0 million in gross proceeds from an at-the-market (ATM) program in July 2025.
- NuCana announced encouraging data for its lead anti-cancer medicines, NUC-7738 and NUC-3373, and expects to announce initial data from the Phase 1/2 expansion study of NUC-7738 in Q4 2025.
Nov 13, 2025, 9:18 PM
NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
NCNA
New Projects/Investments
Guidance Update
- NuCana plc announced the publication of new data from the NuTide:303 clinical study of NUC-3373 in combination with pembrolizumab, along with complementary preclinical findings, on October 14, 2025.
- The study demonstrated a favorable efficacy and safety profile for NUC-3373 plus pembrolizumab in heavily pre-treated patients with advanced solid tumors.
- Key clinical findings include a patient with metastatic melanoma remaining progression-free at 23 months with a durable partial response, and a patient with urothelial carcinoma of the bladder achieving a 100% reduction in tumor lesion size and staying on treatment for over 15 months.
- Preclinical data supports these findings, showing NUC-3373 promotes the release of immunogenic damage-associated molecular patterns (DAMPs), enhances activation of natural killer (NK) cells, and, in combination with a PD-1 inhibitor, enhances tumor cell death.
- NuCana anticipates maintaining its cash runway into 2029.
Oct 14, 2025, 12:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more